content_image/162755.jpg
## Sales by Geographical Area 

<img src='content_image/162755.jpg'>

Note: Sales by geographical area are calculated according to the location of sellers. 

## Japan 

Sales in Japan including revenues related to exports and licenses decreased 1.1% year on year, to ¥530.6 billion. Sales in the Japanese market rose by 0.2% from the previ- ous fiscal year to ¥515.6 billion. Although there was an impact of generics, sales remained largely unchanged in fiscal 2013 from the previous year due to steady expansion in sales of growing mainstay products and new products. 

In addition to Betanis, products such as Micardis (including its combination drugs, Micombi and Micamlo) for the treatment of hypertension, Celecox, an anti-inflammatory and anti-pain drug, Symbicort for the treatment of bronchial asthma, Bonoteo for the treatment of osteoporosis and vaccines showed growth in sales. There were also contri- butions from sales of new products including Cimzia for the treatment of adult patients with rheumatoid arthritis and Gonax for the treatment of prostate cancer. Sales of some products declined, including Lipitor for the treatment of hypercholesterolemia, Seroquel for the treatment of schizo- phrenia, Myslee for the treatment of insomnia and Gaster for the treatment of peptic ulcer and gastritis, mainly due to the impact of generics. Micamlo BP (combination drug) for the treatment of hypertension and Acofide for the treatment of functional dyspepsia were launched in May and June 2013, respectively. Bisono Tape, a transdermal hyperten- sion medication, was launched in September 2013. 

## Americas (Sales in North America and Central and South America) 

Sales in the Americas increased 38.3% year on year, to ¥287.0 billion. On a U.S. dollar basis, sales grew 14.6%, to US$2,863 million. 

Sales of XTANDI and Myrbetriq, launched in the U.S. in September and October 2012 respectively, contributed to 

an increase in sales. In addition, products, such as  VESIcare, and Lexiscan, a pharmacologic stress agent, continuously grew. Also, income from anticancer drug Tarceva increased. Sales of Prograf fell due to the impact of generics. 

## Europe, Middle East and Africa (EMEA) 

Sales in EMEA rose 35.6% year on year, to ¥264.3 billion. On a euro basis, sales also rose 8.1%, to € 1,967 million. 

BETMIGA and XTANDI, which were launched in February and July 2013, respectively, contributed to an overall increase in sales. 

Furthermore, sales of Vesicare and the candin-type antifungal agent MyCAMINE grew. Sales of Prograf, Harnal and prostate cancer treatment Eligard increased mainly due to the foreign exchange rate impact. 

## Asia and Oceania 

In Asia and Oceania, sales rose 35.0% year on year, to ¥58.0 billion. On a basis excluding the impact of foreign exchange, sales increased 10.9% from the previous year. Sales expansion of Prograf, Harnal and Vesicare, led to the increase in revenues. 

## Sales by Product 

* In sales by product, sales of each product and year-on-year changes are based on Japanese accounting standards. 

## Sales of Global Products 

Prograf, Advagraf/ Graceptor/ASTAGRAF (Immunosuppressant) 

Sales in Japan increased by 2.0% to ¥50.4 billion. Sales of the once-daily formulation Graceptor increased steadily. Outside the transplantation area in Japan, Prograf has autoimmune disease indications including rheumatoid arthritis, lupus nephritis, myasthenia gravis, and ulcerative colitis. Its generics were launched in Japan in June 2013. The share of generic products in the tacrolimus market, which includes Prograf and its generics, was approximately 8% during fiscal 2013. 

Sales in the Americas on a U.S. dollar basis decreased by 21.9%, to US$296 million, in fiscal 2013 due to the impact of generic versions. When converted to yen, sales decreased by 5.8%, to ¥29.6 billion. In August 2013, the 

